The purpose of this study is to test the good and bad effects of the drug called durvalumab in combination with the chemotherapy drugs gemcitabine and cisplatin. We are doing this study because we want to find out if this approach is better or worse than the usual approach for liver cancer.

The combination of gemcitabine, cisplatin, and durvalumab has been approved by the U.S. Food and Drug Administration (FDA) as front line therapy for advanced biliary tract cancers, including intrahepatic cholangiocarcinoma.

This trial compares the effect of ASTX727 in combination with iadademstat to ASTX727 alone in treating patients with accelerated or blast phase Philadelphia chromosome negative myeloproliferative neoplasms (MPNs).

The purpose of this study is to test if an investigational study drug, pegozafermin, is safe and effective in treating patients with MASH metabolic dysfunction-associated steatohepatitis (MASH).

The purpose of this study is to determine if investigational Ropeginterferon alfa-2b-njft (P1101) is safe and effective at treating participants with pre-fibrotic/early primary myelofibrosis.

Investigational means that Ropeginterferon alfa-2b-njft (P1101) is not approved by the U.S. Food and Drug Administration.

The purpose of this study is to learn about people’s experiences with Crystal Meth Anonymous (CMA), a 12-step community-based support group for people who use crystal methamphetamine. 

This study will explore whether tirzepatide is a practical and acceptable treatment for postmenopausal women with a history of hormone receptor-positive breast cancer and obesity.

The investigators aim to understand whether participants are willing and able to take this medication once weekly via subcutaneous injection for 6 months and whether it may help improve weight and overall health.

The purpose of this study is to compare the usual treatment with hormonal therapy medications to treatment with low-dose tamoxifen for patients with molecular low-risk early-stage breast cancer.   

This study has 2 study groups. Participants will be randomized by a computer to assign them to one of the study groups.

The purpose of this study is to provide patients with AMTAGVI (lifileucel) that is Out of Specification for Commercial Release.
   
In this study, AMTAGVI will be given intravenously (meaning through a needle in the vein directly into the blood).

Participation is expected to last up to 24 months.

Alpha 1-antitrypsin deficiency is a genetically inherited condition that affects the lungs and/or the liver. It is passed on from parents to their children through genes. It is a progressive condition, which means it may worsen over time. AAT normally protects the lung from damage. In this condition, the AAT protein is abnormal and cannot be released from the liver to protect the lungs. This can result in chronic obstructive pulmonary disease (COPD). It can lead to serious lung and/or liver disease.

The overall objective of our proposal is to gain a comprehensive understanding of the quality of online information about prostate cancer and to investigate the link between consumption of online information with attitudes toward PSA screening to help overcome barriers and reduce disparities in prostate cancer screening.
   
Aim 1: Evaluate the quality and readability of the online information regarding prostate cancer screening utilizing validated questionnaires and our manual and digital assessment tools.